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An 88-year-old man with Alzheimer's dementia who previously received a diagnosis of solitary 
Fuhrman grade 2 renal cell carcinoma1 managed with active surveillance presented to the 
emergency department for progressive left-sided headache and difficulty recognizing numbers 
and letters. He and his family denied history of trauma, fall, or anticoagulant use. This occurred 1 
week after presenting to the same emergency department with a headache and being discharged 
home after negative head computed tomography, 2 months after spontaneous subarachnoid 
hemorrhage involving the right central sulcus, and 11 months after transient ischemic attack 
symptoms with negative workup. Non-contrast head computed tomography revealed a new acute 
gyriform 3.0 × 2.0 cm left parieto-occipital junction hemorrhage (Fig. 1). Subsequent brain 
magnetic resonance imaging with contrast revealed a 1.4 × 1.5 cm left lateral occipital and 0.7 × 
1.8 cm left frontal operculum enhancements (Fig. 2). Radiation oncology was consulted 
regarding management of this patient. 
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Fig. 1. Noncontrast axial computed tomography on initial presentation. 
 Fig. 2. Brain magnetic resonance imaging 48 hours after initial presentation. 
  
Questions 
1. Would you offer radiation therapy to this patient without intracranial diagnosis by pathology? 
2. If so, what modality, field, and dose approach would you employ? 
3. Would you recommend additional systemic therapy? 
